Zacks Investment Research upgraded shares of BIOVERATIV INC (NASDAQ:BIVV) from a sell rating to a hold rating in a research note released on Thursday morning.
According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “
A number of other equities research analysts have also recently issued reports on BIVV. Jefferies Group LLC reiterated a buy rating and issued a $70.00 target price (up from $67.00) on shares of BIOVERATIV INC in a research note on Wednesday, August 9th. Evercore ISI assumed coverage on BIOVERATIV INC in a research note on Wednesday, August 16th. They issued an in-line rating and a $58.00 target price on the stock. Wedbush reiterated a market perform rating on shares of BIOVERATIV INC in a research note on Wednesday, June 28th. Cowen and Company reiterated a buy rating and issued a $80.00 target price on shares of BIOVERATIV INC in a research note on Friday, August 4th. Finally, Credit Suisse Group lifted their price objective on shares of BIOVERATIV INC from $45.00 to $47.00 and gave the company an underperform rating in a research note on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. BIOVERATIV INC has an average rating of Hold and an average price target of $60.43.
BIOVERATIV INC (BIVV) opened at 55.61 on Thursday. The stock has a market cap of $6.02 billion and a PE ratio of 13.22. The firm has a 50 day moving average of $59.69 and a 200-day moving average of $55.78. BIOVERATIV INC has a 12-month low of $41.88 and a 12-month high of $64.41.
BIOVERATIV INC (NASDAQ:BIVV) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.17. The company had revenue of $289.10 million during the quarter, compared to the consensus estimate of $269 million. The business’s quarterly revenue was up 37.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.59 earnings per share. On average, analysts expect that BIOVERATIV INC will post $2.92 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://stocknewstimes.com/2017/08/27/bioverativ-inc-bivv-upgraded-at-zacks-investment-research.html.
In related news, Director Alexander J. Denner acquired 90,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The shares were acquired at an average cost of $55.93 per share, for a total transaction of $5,033,700.00. Following the completion of the purchase, the director now directly owns 5,001 shares in the company, valued at $279,705.93. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Diantha Duvall sold 818 shares of BIOVERATIV INC stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $60.47, for a total value of $49,464.46. Following the transaction, the insider now directly owns 2,128 shares in the company, valued at $128,680.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 93,000 shares of company stock worth $5,212,290.
BIOVERATIV INC Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Get a free copy of the Zacks research report on BIOVERATIV INC (BIVV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with MarketBeat.com's FREE daily email newsletter.
